Cryptococcal meningitis is a fungal infection that mainly affects people with HIV and kills around 135,000 people each year in Sub‑Saharan Africa. Effective treatments exist, but in many places where the disease is common they are expensive, unavailable or hard to give. The fungus enters through the respiratory tract and can remain dormant until a weakened immune system allows it to reach the central nervous system and cause meningitis.
Early symptoms include headache, fever and neck stiffness; later signs can include seizures, loss of consciousness and vision problems. In Lilongwe in 2014 two women, Elube and Patricia, developed persistent headaches that became worse over months. Both arrived at Kamuzu Central Hospital unconscious and were diagnosed with HIV and cryptococcal meningitis. Doctors used lumbar punctures to lower intracranial pressure, which eased severe headaches but did not always prevent long-term harm. Patricia lost her sight more than ten years ago and has not regained it.
Treatment advice has evolved: WHO previously recommended a week of amphotericin B deoxycholate by intravenous drip followed by oral flucytosine four times daily and then fluconazole, and in 2022 it updated guidance to a single high dose of liposomal amphotericin B with 14 days of flucytosine and fluconazole. Health workers note that oral flucytosine four times a day is hard for symptomatic patients, and using a nasogastric tube or crushing tablets can affect the drug's bioavailability.
The Drugs for Neglected Diseases initiative is leading a Phase II study at Kamuzu to simplify treatment by reducing flucytosine from four doses to two. The 5FC HIV‑Crypto trial uses a sustained‑release pellet made by Viatris that can be mixed with water and given by mouth or via nasogastric tube. Partners in the trial include Tanzania's National Institute for Medical Research, the University of North Carolina Project in Lilongwe, the Luxembourg Institute of Health, FARMOVS (a South African clinical research organisation) and St George's, University of London. The trial has enrolled half its participants and results are expected in 2027. Clinicians warn that without treatment the disease has 100 per cent mortality and say greater testing, earlier care and wider use of effective regimens could reduce deaths.
Difficult words
- cryptococcal meningitis — Infection of the brain lining caused by fungus
- dormant — Not active but able to become active later
- intracranial pressure — Pressure inside the skull around the brain
- lumbar puncture — Procedure to remove spinal fluid with a needlelumbar punctures
- bioavailability — Amount of a drug that reaches the bloodstream
- liposomal — Containing tiny fat particles used to carry drugs
- nasogastric tube — Tube passed through the nose into the stomach
- flucytosine — Antifungal drug used to treat serious fungal infections
- amphotericin B deoxycholate — Intravenous antifungal medicine with significant side effects
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What practical problems with oral flucytosine do health workers describe, and how might a sustained‑release pellet help?
- Besides new treatment forms, what steps does the article say could reduce deaths from cryptococcal meningitis?
- What challenges do hospitals in places where the disease is common face when providing the WHO-recommended treatments?
Related articles
Traditional African Diet Reduces Inflammation
A trial in Tanzania found that a traditional plant-based African diet lowered inflammation within two weeks, while a short-term Western diet increased inflammation and weakened immune responses. The results matter for rising non-communicable diseases in Sub-Saharan Africa.
